2026 Richard F. Kefford: Medicine Researcher – H-Index, Publications & Awards

Discipline name	D-Index	World Ranking	Current World Ranking	National Ranking	Current National Ranking	Publications	Citations
Medicine	118	3973	3720	109	105	537	78170

Richard F. Kefford publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Richard F. Kefford sits on this spectrum.

101 publications 1,796+

This scientist: 537 publications — 64th percentile

64% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Richard F. Kefford D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Richard F. Kefford sits on this spectrum.

70 D-Index 217+

This scientist: 118 D-Index — 80th percentile

80% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Research.com Recognitions

2023 - Research.com Medicine in Australia Leader Award
2016 - Fellow of the Australian Academy of Health and Medical Science

Overview

Richard F. Kefford is affiliated with Macquarie University in Australia and has contributed extensively to research in medicine, particularly in oncology and molecular biology. Their work spans several important subfields including immunology and public health, with a focus on cancer immunotherapy and biomarker research.

The scientist's research topics cover a range of areas in cancer treatment and diagnostics. Major themes include:

Cancer Immunotherapy and Biomarkers
Melanoma and MAPK Pathways
CAR-T Cell Therapy Research
Immunotherapy and Immune Responses
Cancer Genomics and Diagnostics
Cutaneous Melanoma Detection and Management
Clinical Practice Guidelines Implementation

Frequent publication venues for their work include:

Clinical Cancer Research
European Journal of Cancer
Cancers
Targeted Oncology
Internal Medicine Journal

Frequent coauthors who have collaborated with Richard F. Kefford are:

Georgina V. Long
Matteo S. Carlino
Alexander M. Menzies
Richard A. Scolyer
Helen Rizos

Among recent research papers, notable publications include:

Transcriptional downregulation of MHC class I and melanoma de-differentiation in resistance to PD-1 inhibition (2020, Nature Communications)
Adjuvant dabrafenib plus trametinib versus placebo in patients with resected, BRAFV600-mutant, stage III melanoma (COMBI-AD): exploratory biomarker analyses from a randomised, phase 3 trial (2020, The Lancet Oncology)
Clinicians' attitudes and perceived barriers and facilitators to cancer treatment clinical practice guideline adherence: a systematic review of qualitative and quantitative literature (2020, Implementation Science)
Longitudinal Monitoring of ctDNA in Patients with Melanoma and Brain Metastases Treated with Immune Checkpoint Inhibitors (2020, Clinical Cancer Research)
Long-term outcomes in patients with BRAF V600-mutant metastatic melanoma receiving dabrafenib monotherapy: Analysis from phase 2 and 3 clinical trials (2020, European Journal of Cancer)

Richard F. Kefford's work has been recognized by their election as a Fellow of the Australian Academy of Health and Medical Science in 2016.

Best Publications

Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma

Omid Hamid;Caroline Robert;Adil Daud;F. Stephen Hodi

4127
Citations
Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations

Keith T. Flaherty;Jeffery R. Infante;Adil Daud;Rene Gonzalez

3234
Citations
Oncogenic Signaling Pathways in The Cancer Genome Atlas

Francisco Sanchez-Vega;Marco Mina;Joshua Armenia;Walid K. Chatila

3193
Citations
Pan-cancer analysis of whole genomes

Peter J. Campbell;Gad Getz;Jan O. Korbel;Joshua M. Stuart

3090
Citations
Genomic Classification of Cutaneous Melanoma

Rehan Akbani;Kadir C. Akdemir;B. Arman Aksoy;Monique Albert

3009
Citations
Cell-of-Origin Patterns Dominate the Molecular Classification of 10,000 Tumors from 33 Types of Cancer.

Katherine A. Hoadley;Christina Yau;Christina Yau;Toshinori Hinoue;Denise M. Wolf

2565
Citations
Survival in BRAF V600–Mutant Advanced Melanoma Treated with Vemurafenib

Jeffrey A. Sosman;Kevin B. Kim;Lynn Schuchter;Rene Gonzalez

2560
Citations
Comprehensive Characterization of Cancer Driver Genes and Mutations.

Matthew H Bailey;Collin Tokheim;Eduard Porta-Pardo;Sohini Sengupta

2512
Citations
Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: A randomised dose-comparison cohort of a phase 1 trial

Caroline Robert;Antoni Ribas;Jedd D. Wolchok;F. Stephen Hodi

2103
Citations
Whole-genome landscapes of major melanoma subtypes

Nicholas K. Hayward;Nicholas K. Hayward;James S. Wilmott;Nicola Waddell;Nicola Waddell;Peter A. Johansson

1492
Citations
Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma

G. V. Long;A. Hauschild;M. Santinami;V. Atkinson

1423
Citations
Prognostic and Clinicopathologic Associations of Oncogenic BRAF in Metastatic Melanoma

Georgina V. Long;Alexander M. Menzies;Adnan M. Nagrial;Lauren E. Haydu

1217
Citations
Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma

Antoni Ribas;Omid Hamid;Adil Daud;F. Stephen Hodi

1154
Citations
Genomic and Functional Approaches to Understanding Cancer Aneuploidy

Alison M. Taylor;Alison M. Taylor;Juliann Shih;Gavin Ha;Gavin Ha;Galen F. Gao

1116
Citations
Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy.

Hubing Shi;Willy Hugo;Xiangju Kong;Aayoung Hong

1042
Citations
Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial.

Gerald S Falchook;Georgina V Long;Georgina V Long;Razelle Kurzrock;Kevin B Kim

1018
Citations
Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial

Georgina V. Long;Uwe Trefzer;Michael A. Davies;Richard F. Kefford

1002
Citations
Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001.

O. Hamid;C. Robert;C. Robert;A. Daud;F.S. Hodi

936
Citations
Phase III Randomized Clinical Trial Comparing Tremelimumab With Standard-of-Care Chemotherapy in Patients With Advanced Melanoma

Antoni Ribas;Richard Kefford;Margaret A. Marshall;Cornelis J.A. Punt

883
Citations
Melanoma whole-exome sequencing identifies (V600E)B-RAF amplification-mediated acquired B-RAF inhibitor resistance.

Hubing Shi;Gatien Moriceau;Xiangju Kong;Mi Kyung Lee

771
Citations

Frequent Co-Authors

Georgina V. Long University of Sydney

Richard A. Scolyer Royal Prince Alfred Hospital

Helen Rizos Macquarie University

Alexander M. Menzies University of Sydney

Matteo S. Carlino University of Sydney

Graham J. Mann Australian National University

John F. Thompson University of Sydney

Caroline Robert University of Paris-Saclay

Antoni Ribas University of California, Los Angeles

Peter Hersey University of Sydney

External Links

Personal website of Richard F. Kefford

If you think any of the details on this page are incorrect, let us know.

Related Online Degrees & Career Pathways

Exploring medical careers in the USA extends far beyond the traditional MD route. Nursing pathways, in particular, offer a range of flexible online options that can accelerate your healthcare career. For those already holding an RN license, consider the best online rn to bsn programs without clinical requirements. These programs allow working nurses to advance their qualifications with minimal disruption and without additional in-person clinical hours.

Ambitious nurses looking to elevate their practice may be interested in more advanced degrees, such as the Doctor of Nursing Practice. If time is a priority, explore dnp online programs designed for fast completion. Some options are also recognized as the easiest dnp programs, focusing on streamlined coursework and supportive learning environments.

For those starting out or seeking an entry point into nursing, fast track lpn options provide a quicker pathway to becoming a Licensed Practical Nurse fully online. Whether advancing a current career or stepping into healthcare for the first time, these online programs offer flexible, accessible opportunities for anyone aspiring to work in medicine in the USA.